Who was the more successful? Who was the more capable? Who accumulated the most victories? Who has the greatest legacy? Who ...

Discover Eton Pharmaceuticals' Q1 2025 financials: robust revenue growth, new product launches, and strong pipeline advancements.

DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and ...

The acquisition and relaunch of Galzin have been well-received, with robust patient services and a $0 co-pay, improving access and affordability for Wilson disease patients. Eton Pharmaceuticals ...

Eton Pharmaceuticals reported a robust first quarter for 2025, with revenue far surpassing expectations. The company achieved a revenue of $17.3 million, marking a 117% increase from the same ...

In the preceding three months, 4 analysts have released ratings for Eton Pharmaceuticals (NASDAQ:ETON), presenting a wide array of perspectives from bullish to bearish. The following table ...

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago.

Authorities are reviewing startup investor General Catalyst’s bid to make Summa Health in Akron, Ohio, a blueprint for the ...

Digital Products and Services, said in a statement. “We’re giving audiences an even more convenient way to access CNN’s trusted reporting and original programming—brought together in one ...

Crypto projects need more favorable valuation-to-revenue ratios to attract more venture capital money, says 10T Holdings' Dan ...